影像诊断与介入放射学

参考文献

[1]SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.

[2]中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2024年版)[J].协和医学杂志, 2024,15(3):532-558.

[3]SALEM R, GABR A, RIAZ A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience[J]. Hepatology, 2018,68(4):1429-1440.

[4]YU Q, KHANJYAN M, FIDELMAN N, et al. Contemporary applications of Y90 for the treatment of hepatocellular carcinoma[J]. Hepatol Commun, 2023,7(10):e0288.

[5]HILGARD P, HAMAMI M, FOULY A E, et al.Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma:European experience on safety and long-term survival[J]. Hepatology, 2010,52(5):1741-1749.

[6]SALEM R, LEWANDOWSKI R J, ATASSI B, et al. Treatment of unresectable hepatocellular carcinoma with use of90Y microspheres(Thera Sphere):safety, tumor response, and survival[J]. J Vasc Interv Radiol, 2005,16(12):1627-1639.

[7]中国医师协会介入医师分会临床诊疗指南专委会,中国研究型医院学会肝胆胰外科专业委员会.钇-90微球选择性内放射治疗肝脏恶性肿瘤规范化操作专家共识（2024版）[J].中华医学杂志, 2024,104(7):486-498.

[8]LEE S Y , JEON S I, JUNG S, et al. Targeted multimodal imaging modalities[J]. Adv Drug Deliv Rev, 2014,76:60-78.

[9]中国临床肿瘤学会核医学专家委员会,北京市核医学质量控制和改进中心.钇-90(90Y)微球选择性内放射治疗原发性和转移性肝癌的中国专家共识[J].中华肝脏病杂志, 2021,29(7):648-658.

[10]REIG M, SANDUZZI-ZAMPARELLI M, FORNER A, et al. BCLC strategy for prognosis prediction and treatment recommendations:the 2025 update[J]. J Hepatol, 2025(2025-10-27)[2025-10-30].https://doi.org/10.1016/j.jhep.2025.10.020.

[11]VILLALOBOS A, PISANIE J L D, GANDHI R T, et al.Yttrium-90 radioembolization dosimetry:dose considerations,optimization, and tips[J]. Semin Intervent Radiol, 2024,41(1):63-78.

[12]KIM H C, CHOI J W, LEE M, et al. Lung shunt reduction for yttrium-90 radioembolization:chemoembolization versus radioembolization[J]. In Vivo, 2021,35(4):2305-2312.

[13]RIAZ A, LEWANDOWSKI R J, KULIK L M, et al. Complications following radioembolization with yttrium-90 microspheres:a comprehensive literature review[J]. J Vasc Interv Radiol, 2009,20(9):1121-1131.

[14]BRUIX J, SHERMAN M. Management of hepatocellular carcinoma:an update[J]. Hepatology, 2011,53(3):1020-1022.

[15]SPARCHEZ Z, CRACIUN R, CARAIANI C, et al. Ultrasound or sectional imaging techniques as screening tools for hepatocellular carcinoma:fall forward or move forward?[J]. J Clin Med, 2021,10(5):903.

[16]TANG A, CRUITE I, MITCHELL D G, et al. Hepatocellular carcinoma imaging systems:why they exist, how they have evolved, and how they differ[J]. Abdom Radiol, 2018,43(1):3-12.

[17]NAKAMURA Y, HIGAKI T, HONDA Y, et al. Advanced CT techniques for assessing hepatocellular carcinoma[J]. Radiol Med,2021,126(7):925-935.

[18]ZHONG H, ZHANG Y, ZHU G B, et al. Preoperative prediction of microvascular invasion and relapse-free survival in hepatocellular Carcinoma≥3 cm using CT radiomics:development and external validation[J]. BMC Med Imaging,2025,25(1):141.

[19]KIERANS A S, KANG S K, ROSENKRANTZ A B. The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm:a meta-analysis[J]. Radiology, 2016,278(1):82-94.

[20]YOON J H, CHANG W, KIM Y K, et al. Comparison of gadoxetic acid-enhanced liver magnetic resonance imaging and contrast-enhanced computed tomography for the noninvasive diagnosis of hepatocellular carcinoma[J]. Liver Cancer, 2025,14(5):638-650.

[21]LÜDEMANN W M, KAHN J, PUSTELNIK D, et al. Yttrium-90radioembolization for unresectable hepatocellular carcinoma:predictive modeling strategies to anticipate tumor response and improve patient selection[J]. Eur Radiol, 2022 ,32(7):4687-4698.

[22]NA S J, OH J K, HYUN S H, et al.18F-FDG PET/CT can predict survival of advanced hepatocellular carcinoma patients:a multicenter retrospective cohort study[J]. J Nucl Med, 2017,58(5):730-736.

[23]FILIPPI L, SCHILLACI O, BAGNI O. Recent advances in PET probes for hepatocellular carcinoma characterization[J]. Expert Rev Med Devices, 2019,16(5):341-350.

[24]WANG H, RUBADEUX D, TROUT A T, et al. Ultrasound-MRI agreement in individuals undergoing surveillance of fontanassociated liver disease[J]. J Comput Assist Tomogr, 2025, 49(5):705-713.

[25]TARAO K, NOZAKI A, KOMATSU H, et al. Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma[J]. World J Hepatol,2021,13(6):699-708.

[26]CHEUNG A L, ZHANG L, LIU C, et al. Evaluation of multisource adaptive MRI fusion for gross tumor volume delineation of hepatocellular carcinoma[J]. Front Oncol, 2022,12:816678.

[27]LIU D M, SALEM R, BUI J T, et al. Angiographic considerations in patients undergoing liver-directed therapy[J].J Vasc Interv Radiol, 2005,16(7):911-935.

[28]HIATT J R, GABBAY J, BUSUTTIL R W. Surgical anatomy of the hepatic arteries in 1000 cases[J]. Ann Surg, 1994,220(1):50-52.

[29]MICHELS N A. Newer anatomy of the liver and its variant blood supply and collateral circulation[J]. Am J Surg, 1966,112(3):337-347.

[30]JOO S M, KIM Y P, YUM T J, et al. Optimized performance of flightplan during chemoembolization for hepatocellular carcinoma:importance of the proportion of segmented tumor area[J]. Korean J Radiol, 2016,17(5):771-778.

[31]AHMED R M, ALI W A, ABDELHAKAM A M, et al. Detection of hepatocellular carcinoma feeding vessels:MDCT angiography with 3D reconstruction versus digital subtraction angiography[J].BMC Med Imaging, 2024,24(1):250.

[32]YUAN H J, LI X, TIAN X M, et al. Comparison of Angio-CT and cone-beam CT-guided immediate radiofrequency ablation after transcatheter arterial chemoembolization for large hepatocellular carcinoma[J]. Abdom Radiol, 2020,45(8):2585-2592.

[33]ZHONG B Y, JIA Z Z, ZHANG W, et al. Application of cone-beam computed tomography in interventional therapies for liver malignancy:a consensus statement by the Chinese college of interventionalists[J]. J Clin Transl Hepatol, 2024,12(10):886-891.

[34]CAMACHO J C, MONCAYO V, KOKABI N, et al.90Y radioembolization:multimodality imaging pattern approach with angiographic correlation for optimized target therapy delivery[J].Radiographics, 2015,35(5):1602-1618.

[35]PUNG L, AHMAD M, MUELLER K, et al. The role of cone-beam CT in transcatheter arterial chemoembolization for hepatocellular carcinoma:a systematic review and meta-analysis[J]. J Vasc Interv Radiol, 2017,28(3):334-341.

[36]TANAKA T, ARAI Y, INABA Y, et al. Current role of hybrid CT/angiography system compared with C-arm cone beam CT for interventional oncology[J]. Br J Radiol, 2014,87(1041):20140126.

[37]宋子阳,邵国良. Angio-CT的优势及其在介入放射学中的应用[J].介入放射学杂志, 2023,32(11):1138-1142.

[38]LIN E Y, JONES A K, CHINTALAPANI G, et al. Comparative analysis of intra-arterial cone-beam versus conventional computed tomography during hepatic arteriography for transarterial chemoembolization planning[J]. Cardiovasc Intervent Radiol ,2019,42(4):591-600.

[39]LIONBERG A, NIJHAWAN K, NAVULURI R, et al. Hybrid angiography-CT for transarterial radioembolization:a pictorial essay[J]. Abdom Radiol, 2021, 46(6):2850-2854.

[40]LEWANDOWSKI R J, SATO K T, ATASSI B, et al.Radioembolization with90Y microspheres:angiographic and technical considerations[J]. Cardiovasc Intervent Radiol, 2007,30(4):571-592.

[41]RHEE T K, OMARY R A, GATES V, et al. The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2005, 16(8):1085-1091.

[42]GR魻ZINGER G, KUPFERSCHLÄGER J, DITTMANN H, et al.Assessment of the parenchymal blood volume by C-arm computed tomography for radioembolization dosimetry[J]. Eur J Radiol, 2016,85(9):1525-1531.

[43]CAMPBELL G S, REED D K, DESAI A, et al. Liver tumor enhancement at hybrid angio-CT and comparison with tumor and hepatic parenchymal distribution of yttrium-90 microspheres by positron emission tomography[J]. Cureus, 2023,15(12):e49861.

[44]RODR魱GUEZ-FRAILE M, EZPONDA A, GRISANTI F, et al.The joint use of99mTc-MAA-SPECT/CT and cone-beam CT optimizes radioembolization planning[J]. EJNMMI Res, 2021,11(1):23.

[45]O’DOHERTY J, SCUFFHAM J, HINTON P. The importance of scatter correction for the assessment of lung shunting prior to yttrium-90 radioembolization therapy[J]. Nucl Med Commun,2011,32(7):628-634.

[46]DICKSON J C, ARMSTRONG I S, GABIÑA P M, et al. EANM practice guideline for quantitative SPECT-CT[J]. Eur J Nucl Med Mol Imaging, 2023,50(4):980-995.

[47]AHMADZADEHFAR H, SABET A, BIERMANN K, et al. The significance of99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for90Y-microsphere selective internal radiation treatment[J]. J Nucl Med, 2010,51(8):1206-1212.

[48]GNESIN S, CANETTI L, ADIB S, et al. Partition model-based99mTc-MAA SPECT/CT predictive dosimetry compared with90Y TOF PET/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma:a quantitative agreement comparison[J]. J Nucl Med, 2016,57(11):1672-1678.

[49]LOUIE J D, KOTHARY N, KUO W T, et al. Incorporating cone-beam CT into the treatment planning for yttrium-90radioembolization[J]. J Vasc Interv Radiol, 2009,20(5):606-613.

[50]JAFARGHOLI RANGRAZ E, COUDYZER W, MALEUX G, et al. Multi-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization[J]. EJNMMI Res, 2019,9(1):19.

[51]WONDERGEM M, SMITS M L, ELSCHOT M, et al.99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of90Y resin microspheres in hepatic radioembolization[J]. J Nucl Med, 2013,54(8):1294-1301.

[52]AHMADZADEHFAR H, DUAN H, HAUG A R, et al. The role of SPECT/CT in radioembolization of liver tumours[J]. Eur J Nucl Med Mol Imaging, 2014,41 Suppl 1:S115-S124.

[53]MANSBERG R, SORENSEN N, MANSBERG V, et al. Yttrium90 Bremsstrahlung SPECT/CT scan demonstrating areas of tracer/tumour uptake[J]. Eur J Nucl Med Mol Imaging, 2007,34(11):1887.

[54]ELSCHOT M, VERMOLEN B J, LAM MG, et al. Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization[J]. PLo S One, 2013,8(2):e55742.

[55]KAO Y H, STEINBERG J D, TAY Y S, et al. Post-radioembolization yttrium-90 PET/CT:part 2:dose-response and tumor predictive dosimetry for resin microspheres[J]. EJNMMI Res, 2013,3(1):57.

[56]ALSULTAN A A, SMITS M L J, BARENTSZ M W, et al. The value of yttrium-90 PET/CT after hepatic radioembolization:a pictorial essay[J]. Clin Transl Imaging, 2019,7(4):303-312.

[57]ZEIMPEKIS K G, SARI H, G魻ZLÜG魻L N, et al. Evaluation of long axial field-of-view(LAFOV)PET/CT for post-treatment dosimetry in yttrium-90 radioembolization of liver tumors:a comparative study with conventional SPECT imaging[J]. Eur J Nucl Med Mol Imaging, 2025,52(4):1460-1471.

[58]MARTINEZ-LUCIO T S, MENDOZA-IBAÑEZ O I, LIU W L, et al. Long axial field of view PET/CT:technical aspects in cardiovascular diseases[J]. Semin Nucl Med, 2025,55(1):52-66.

[59]MENDIZABAL M, REDDY K R. Current management of hepatocellular carcinoma[J]. Med Clin North Am, 2009,93(4):885-900.

[60]DELANEY L J, TANTAWI M, WESSNER C E, et al. Predicting long-term hepatocellular carcinoma response to transarterial radioembolization using contrast-enhanced ultrasound:initial experiences[J]. Ultrasound Med Biol, 2021,47(9):2523-2531.

[61]YAGHMAI V, BESA C, KIM E, et al. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy[J]. Am J Roentgenol, 2013,201(1):80-96.

[62]IPPOLITO D, INCHINGOLO R, GRAZIOLI L, et al. Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma[J]. World J Gastroenterol, 2018,24(23):2413-2426.

[63]CHOI J Y, LEE J M, SIRLIN C B. CT and MR imaging diagnosis and staging of hepatocellular carcinoma:part II.Extracellular agents, hepatobiliary agents, and ancillary imaging features[J]. Radiology, 2014, 273(1):30-50.

[64]KIM I, KIM M J. Histologic characteristics of hepatocellular carcinomas showing atypical enhancement patterns on 4-phase MDCT examination[J]. Korean J Radiol, 2012,13(5):586-593.

[65]SILVA A C, MORSE B G, HARA A K, et al. Dual-energy(spectral)CT:applications in abdominal imaging[J]. Radiographics,2011,31(4):1031-1050.

[66]WANG A S, HSIEH S S, PELC N J.双能CT的基本原理、应用和未来展望[J]. CT理论与应用研究, 2012,21(3):367-386.

[67]ALTENBERND J, WETTER A, FORSTING M, et al. Treatment response after radioembolisation in patients with hepatocellular carcinoma:an evaluation with dual energy computed-tomography[J]. Eur J Radiol Open, 2016,3:230-235.

[68]CHARTAMPILAS E, RAFAILIDIS V, GEORGOPOULOU V, et al. Current imaging diagnosis of hepatocellular carcinoma[J].Cancers, 2022, 14(16):3997.

[69]IPPOLITO D, PECORELLI A, QUERQUES G, et al. Dynamic computed tomography perfusion imaging:complementary diagnostic tool in hepatocellular carcinoma assessment from diagnosis to treatment follow-up[J]. Acad Radiol, 2019,26(12):1675-1685.

[70]REINER C S, MORSBACH F, SAH B R, et al. Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion[J]. J Vasc Interv Radiol, 2014,25(5):747-759.

[71]BEVILACQUA A, MALAVASI S, VILGRAIN V. Liver CT perfusion:which is the relevant delay that reduces radiation dose and maintains diagnostic accuracy?[J]. Eur Radiol, 2019,29(12):6550-6558.

[72]KALARAKIS G, PERISINAKIS K, AKOUMIANAKIS E, et al.CT liver perfusion in patients with hepatocellular carcinoma:can we modify acquisition protocol to reduce patient exposure?[J].Eur Radiol, 2021,31(3):1410-1419.

[73]GUO J, SEO Y, REN S, et al. Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma:direct comparison and a meta-analysis[J]. Abdom Radiol, 2016,41(10):1960-1972.

[74]PARK H J, CHOI B I, LEE E S, et al. How to differentiate borderline hepatic nodules in hepatocarcinogenesis:emphasis on imaging diagnosis[J]. Liver Cancer, 2017,6(3):189-203.

[75]KIM T H, YOON J H, LEE J M. Emerging role of hepatobiliary magnetic resonance contrast media and contrast-enhanced ultrasound for noninvasive diagnosis of hepatocellular carcinoma:emphasis on recent updates in major guidelines[J]. Korean J Radiol, 2019,20(6):863-879.

[76]JOO I, KIM S Y, KANG T W, et al. Radiologic-pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid-enhanced MRI:a multicenter study[J]. Radiology, 2020,296(2):335-345.

[77]KOH D M, COLLINS D J. Diffusion-weighted MRI in the body:applications and challenges inoncology[J]. Am J Roentgenol, 2007,188(6):1622-1635.

[78]TAOULI B, KOH D M. Diffusion-weighted MR imaging of the liver[J]. Radiology, 2010,254(1):47-66.

[79]DENG J, MILLER F H, RHEE T K, et al. Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization[J]. J Vasc Interv Radiol, 2006,17(7):1195-1200.

[80]KAMEL I R, REYES D K, LIAPI E, et al. Functional MR imaging assessment of tumor response after90Y microsphere treatment in patients with unresectable hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2007,18(1 Pt 1):49-56.

[81]RHEETK,NAIKNK,DENGJ,etal.Tumorresponseafteryttrium-90radioembolization for hepatocellular carcinoma:comparison of diffusion-weighted functional MR imaging with anatomic MR imaging[J]. J Vasc Interv Radiol, 2008,19(8):1180-1186.

[82]HAMSTRA D A, REHEMTULLA A, ROSS B D. Diffusion magnetic resonance imaging:a biomarker for treatment response in oncology[J]. J Clin Oncol, 2007,25(26):4104-4109.

[83]KOKABI N, CAMACHO J C, XING M, et al. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis[J]. Abdom Imaging, 2014,39(5):969-978.

[84]CRUITE I, SCHROEDER M, MERKLE E M, et al. Gadoxetate disodium-enhanced MRI of the liver:part 2, protocol optimization and lesion appearance in the cirrhotic liver[J]. Am J Roentgenol, 2010,195(1):29-41.

[85]CHIU R Y, YAP W W, PATEL R, et al. Hepatocellular carcinoma post embolotherapy:imaging appearances and pitfalls on computed tomography and magnetic resonance imaging[J].Can Assoc Radiol J, 2016,67(2):158-172.

[86]KIM S, MANNELLI L, HAJDU C H, et al. Hepatocellular carcinoma:assessment of response to transarterial chemoembolization with image subtraction[J]. J Magn Reson Imaging, 2010,31(2):348-355.

[87]CANNELLA R, SARTORIS R, GR魪GORY J, et al. Quantitative magnetic resonance imaging for focal liver lesions:bridging the gap between research and clinical practice[J]. Br J Radiol, 2021,94(1122):20210220.

[88]TAOULI B, JOHNSON R S, HAJDU C H, et al. Hepatocellular carcinoma:perfusion quantification with dynamic contrastenhanced MRI[J]. Am J Roentgenol, 2013,201(4):795d800.

[89]WEISS J, RUFF C, GROSSE U, et al. Assessment of hepatic perfusion using GRASP MRI:bringing liver MRI on a new level[J]. Invest Radiol, 2019,54(12):737-743.

[90]BASHA M A A, ALAZZAZY M Z, AHMED A F, et al. Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study[J]. Eur Radiol , 2018 , 28(6):2592-2603.

[91]GÁMEZ-CENZANO C, PINO-SORROCHE F. Standardization and quantification in FDG-PET/CT imaging for staging and restaging of malignant disease[J]. PET Clin, 2014,9(2):117-127.

[92]OZAKI K, HARADA K, TERAYAMA N, et al. FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background[J]. Jpn J Radiol, 2020,38(8):697-718.

[93]JREIGE M, MITSAKIS P, VAN DER GUCHT A, et al.18F-FDG PET/CT predicts survival after90Y transarterial radioembolization in unresectable hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging, 2017,44(7):1215-1222.

[94]ZERIZER I, AL-NAHHAS A, TOWEY D, et al. The role of early18F-FDG PET/CT in prediction of progression-free survival after90Y radioembolization:comparison with RECIST and tumour density criteria[J]. Eur J Nucl Med Mol Imaging, 2012,39(9):1391-1399.

[95]REIZINE E, CHALAYE J, MULE S, et al. Utility of early posttreatment PET/CT evaluation using FDG or18F-FCH to predict response to90Y radioembolization in patients with hepatocellular carcinoma[J]. Am J Roentgenol, 2022,218(2):359-369.

[96]NENSA F, BAMBERG F, RISCHPLER C, et al. Hybrid cardiac imaging using PET/MRI:a joint position statement by the European Society of Cardiovascular Radiology(ESCR)and the European Association of Nuclear Medicine(EANM)[J]. Eur Radiol, 2018,28(10):4086-4101.

[97]MUZIC R F JR, DIFILIPPO F P. Positron emission tomographymagnetic resonance imaging:technical review[J]. Semin Roentgenol, 2014,49(3):242-254.

[98]SEMAAN S, MAKKAR J, LEWIS S, et al. Imaging of hepatocellular carcinoma response after90Y radioembolization[J].Am J Roentgenol, 2017,209(5):W263-W276.

[99]FOWLER K J, MAUGHAN N M, LAFOREST R, et al.PET/MRI of hepatic90Y microsphere deposition determines individual tumor response[J]. Cardiovasc Intervent Radiol, 2016,39(6):855-864.

[100]LEVILLAIN H, DURAN DERIJCKERE I, MARIN G, et al.90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer[J]. EJNMMI Res, 2018,8(1):60.

[101]HESSE M, D’ABADIE P, LHOMMEL R, et al. Yttrium-90TOF-PET-based EUD predicts response post liver radioembolizations using recommended manufacturer FDG reconstruction parameters[J]. Front Oncol, 2021,11:592529.

[102]CONTI M. State of the art and challenges of time-of-flight PET[J]. Phys Med, 2009,25(1):1-11.

[103]ROOSEN J, KLAASSEN N J M, WESTLUND GOTBY L E L, et al. To 1000 Gy and back again:a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer[J]. Eur J Nucl Med Mol Imaging, 2021,48(12):3776-3790.

[104]JOO I, KIM H C, KIM G M, et al. Imaging evaluation following90Y radioembolization of liver tumors:what radiologists should know[J]. Korean J Radiol, 2018,19(2):209-222.

[105]IBRAHIM S M, NIKOLAIDIS P, MILLER F H, et al.Radiologic findings following Y90 radioembolization for primary liver malignancies[J]. Abdom Imaging, 2009,34(5):566-581.

[106]VOUCHE M, HABIB A, WARD T J, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation:multicenter radiology-pathology correlation and survival of radiation segmentectomy[J]. Hepatology, 2014,60(1):192-201.

[107]KAMEL I R, BLUEMKE D A, ENG J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma[J].J Vasc Interv Radiol, 2006,17(3):505-512.

[108]ATASSI B, BANGASH A K, BAHRANI A, et al. Multimodality imaging following90Y radioembolization:a comprehensive review and pictorial essay[J]. Radiographics, 2008,28(1):81-99.

[109]BEKKI Y, MAHAMID A, LEWIS S, et al. Radiological and pathological assessment with EOB-MRI after Y90 radiation lobectomy prior to liver resection for hepatocellular carcinoma[J]. HPB, 2022,24(12):2185-2192.

[110]ALEM Z, MURRAY T E, EGRI C, et al. Treatment response assessment following transarterial radioembolization for hepatocellularcarcinoma[J]. Abdom Radiol, 2021,46(8):3596-3614.